Biomarkers for assessing peripheral neuropathy response to cancer treatment

• US 9,605,317 B2
• Filed: 03/24/2010
• Issued: 03/28/2017
• Est. Priority Date: 03/24/2009
• Status: Expired due to Fees

• Current Assignee: Janssen Pharmaceutica NV (Johnson & Johnson)
• Original Assignee: Janssen Pharmaceutica NV (Johnson & Johnson)
• Inventors: Cohen, Nadine, Favis, Reyna, Li, Qingqin, Ricci, Deborah, Sun, Yu, van de Velde, Helgi
• Primary Examiner(s): Kolker, Daniel E
• Assistant Examiner(s): Dutt, Aditi
• Application Number:
  US12/730,587
• Publication Number:
  US 20100249065A1
• Time in Patent Office: 2,561 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/172 Haplotypes

Abstract

The present invention provides methods for identifying patients at increased risk of developing an adverse neurological event in response to a cancer treatment. Methods also include modifying the treatment regimen of said patent dependent on the presence or absence of biomarkers in the patient.

Claims

1. A method of treating a patient with cancer, the method comprising:

a. performing an assay on the patient'"'"'s DNA to determine the presence or absence of a biomarker;

wherein said biomarker is selected from the group consisting of a homozygous genotype of the minor allele, G, of rs4553808, a homozygous genotype of the minor allele, G, of rs1474642, a homozygous genotype of the minor allele, G, of rs12568757, a homozygous genotype of the minor allele, A, of rs11974610, 1 or 2 copies of the minor allele, G, of rs916758 and 1 or 2 copies of the minor allele, T, of rs1261134; and

,

b. administering bortezomib to the patient lacking said biomarker.

2. The method of claim 1, wherein said biomarker is the homozygous genotype of the minor allele, G, of rs4553808.

3. The method of claim 1, wherein said biomarker is the homozygous genotype of the minor allele, G, of rs1474642.

4. The method of claim 1, wherein said biomarker is the homozygous genotype of the minor allele, G, of rs12568757.

5. The method of claim 1, wherein said biomarker is the homozygous genotype of the minor allele, A, of rs11974610.

6. The method of claim 1, wherein said biomarker is 1 or 2 copies of the minor allele, G, of rs916758.

7. The method of claim 1, wherein said biomarker is 1 or 2 copies of the minor allele, T, of rs1261134.